ValiRx inks deal with Dundee Drug Discovery Unit
12th Feb 2024 12:59
(Sharecast News) - ValiRx announced the signing of a significant agreement with the University of Dundee and its Drug Discovery Unit (DDU) on Monday.
Read moreValiRx enters option deal with Ambrose Healthcare
5th Dec 2023 15:08
(Sharecast News) - Cancer therapeutics-focussed life science company ValiRx announced on Tuesday that its subsidiary ValiSeek has entered into an exclusive option agreement with Ambrose Healthcare, a private UK-based pharmaceutical company.
Read moreValiRx enters partnership with StingRay Bio
10th Nov 2023 10:32
(Sharecast News) - Life science company ValiRx announced a new partnership with StingRay Bio on Friday, aiming to explore a promising lead series of drug candidates designed for oncology applications.
Read moreValiRx shares jump as H1 losses shrink
24th Aug 2023 09:59
(Sharecast News) - Shares in ValiRx jumped nearly on Thursday after the biotech posted results for its first half, in which losses per share shrunk by a third.
Read moreValiRx subsidiary Inaphaea signs deal with Agility Life Sciences
14th Aug 2023 09:53
(Sharecast News) - Life science company ValiRx announced on Monday that its wholly-owned subsidiary Inaphaea BioLabs has entered a collaborative services agreement with Agility Life Sciences.
Read moreValiRx terminates collaboration with Hokkaido University
16th Jun 2023 11:14
(Sharecast News) - Life science company ValiRx has officially concluded its evaluation agreement with Hokkaido University, it announced on Friday.
Read moreValiRx acquires assets of in-liquidation Imagen Therapeutics
14th Jun 2023 14:37
(Sharecast News) - Life science company ValiRx has successfully completed the acquisition of the scientific assets of Imagen Therapeutics, it announced on Wednesday.
Read moreValiRx incorporates new wholly-owned lab subsidiary
1st Mar 2023 14:26
(Sharecast News) - Life science company ValiRx announced the incorporation of a new wholly-owned subsidiary, Inaphaea BioLabs, on Wednesday.
Read moreValiRx forms new majority-owned breast cancer subsidiary
24th Oct 2022 12:47
(Sharecast News) - Women's health and cancer therapeutics company ValiRx announced the formation of a new partially-owned subsidiary, Cytolytix, on Monday, which had signed an intellectual property licence agreement with King's College London (KCL).
Read moreValiRx expecting to grant extension of exclusivity to TheoremRx
17th Jun 2022 13:55
(Sharecast News) - Cancer therapeutics and women's health-focussed ValiRx updated the market on its proposed sub-licensing agreement with TheoremRx for 'VAL201' on Friday.
Read moreValiRx amends longstanding licence deal with Cancer Research Technology
20th Dec 2021 12:17
(Sharecast News) - Cancer therapeutics developer ValiRx announced on Monday that it has amended and restated the licence for the VAL201 peptide held by the company from Cancer Research Technology (CRT) to enable a range of sub-licensing options.
Read moreValiRx adds three new patents in first half
6th Jul 2021 13:00
(Sharecast News) - Clinical-stage drug development company ValiRx updated the market on its patent portfolio on Tuesday, reporting that it had continued to build its intellectual property position in the first half of the year.
Read moreValiRx terminates peptide drug candidate deal
27th May 2021 13:54
(Sharecast News) - Clinical-stage drug development company ValiRx announced on Thursday that it has ended its agreement over the evaluation of the 'KTH222' peptide as a drug candidate for treating patients with ovarian cancer.
Read morePhysiomics and ValiRx enter new collaboration deal
15th Feb 2021 16:04
(Sharecast News) - Oncology consulting company Physiomics has entered into a new agreement with clinical-stage drug development company ValiRx, it announced on Monday, superseding the agreement between the two companies, which was announced in September 2011.
Read moreValiRx looks to build on portfolio of drug candidates
6th Jul 2020 09:31
(Sharecast News) - Medicines developer ValiRx said on Monday that it was looking to build on its existing portfolio of drug candidates and grow a pipeline of innovative, early-stage projects in the areas of oncology and women's health.
Read more